Why Roche Holdings Stock Withered on Wednesday
For the second trading session in less than a week, Roche Holding (OTC: RHHBY) stock really took it on the chin Wednesday. Dispiriting news about its investigational obesity drug was the culprit; disseminating this, investors sold out of the pharmaceutical veteran. At the end of the day's action, Roche had lost almost 6% of its value.
In a meeting of the European Association for the Study of Diabetes that day, Roche presented the results of an early-stage clinical trial of its CT-996 pill.
This is the Switzerland-based company's bid to compete in the very high-potential weight-loss drug market. At the moment, this is dominated by fellow European pharmaceutical company Novo Nordisk's Wegovy. A more recent arrival, muscular U.S. peer Eli Lilly, is also competing in the segment with its Zepbound.
Source Fool.com
Roche Holding AG ADR Stock
Currently there is a rather positive sentiment for Roche Holding AG ADR with 5 Buy predictions and 3 Sell predictions.
As a result the target price of 46 € shows a slightly positive potential of 5.67% compared to the current price of 43.53 € for Roche Holding AG ADR.
